Fall 2026

IT Co-op

Posted on 7/21/2026

Aspect Biosystems

Aspect Biosystems

51-200 employees

Bioprints allogeneic tissue therapeutics

Compensation Overview

CA$21.63 - CA$23.08/hr

Vancouver, BC, Canada

In Person

Category
IT & Security (1)
Required Skills
LLM
Computer Networking

Get referred to Aspect Biosystems

Find people who can refer or advise you

Requirements
  • Student enrolled in computer science, computer systems technology or similar
  • Expertise in PC and Apple hardware
  • You have a high level of experience in troubleshooting both Windows and Mac operating systems, networking issues, and have worked in a customer service role
  • Demonstrated ability to identify innovative working solutions to problems with challenging constraints
  • Superior written and verbal communication skills.You are an active listener who can communicate to different audiences in diverse situations
  • Outstanding attention to detail, and experimental and process rigour. You take pride in your work and strive for excellence in the work you do
  • Go-Getter: You work with a sense of urgency, are results-driven, and thrive in a fast-paced, interdisciplinary, and entrepreneurial environment. You are willing to roll up your sleeves and do what it takes to get the job done
Responsibilities
  • Provide support to Aspect team on a variety of IT requests and problems
  • Troubleshoot PC’s, printers, network, and remote desktop
  • Workstation administration and system setup
  • Onboarding new employees and offboarding the ones that leave
  • Install and configure applications, diagnose software faults, and solve technical and application problems
  • Maintain hardware inventory
  • Administer user accounts across multiple systems
  • Assist in selecting and deploying new technology to support Aspects goals and objectives
  • Proactively learn and train other staff members on new technologies
  • Provide positive customer experiences when working with users
  • Work with AI Engineering to build simple data pipelines for specific analytical workflows
  • Leverage ecosystem tools to build operational automations in support of various functions (AI Agents, scripted automations)
  • Support Workspace configurations with the aim of establishing ALCOA+ principles
  • Support the software engineering team on other ad hoc projects

Aspect Biosystems develops bioprinted tissue therapeutics for regenerative medicine. Its work centers on a platform that combines proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics for clinical use. The company works through strategic collaborations with leading pharmaceutical and biotechnology firms, funded by partnerships and investors. The product approach uses bioprinting to assemble tissue constructs layer by layer from cells and biomaterials, guided by computational design, producing off-the-shelf (allogeneic) tissue therapies. What sets the company apart is its integrated platform, a focus on allogeneic, scalable tissue products, and a collaboration-driven business model with strong industry partnerships, backed by a solid funding base. Its goal is to advance regenerative medicine by delivering a targeted pipeline of bioprinted tissue therapeutics through collaborations and continued investment.

Company Size

51-200

Company Stage

N/A

Total Funding

$294.8M

Headquarters

Vancouver, Canada

Founded

2013

Get referred to Aspect Biosystems

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The $2.6B Novo Nordisk partnership secures massive revenue and validates the bioprinting technology for diabetes treatments.
  • Recent $79M government funding accelerates the $280M project for cellular medicines targeting endocrine and metabolic diseases.
  • Preclinical data showed adrenal tissue therapeutics restored hormone function in animals for six months, proving platform efficacy.

What critics are saying

  • Dependency on Novo Nordisk creates existential risk if they delay trials or pivot to gene therapies within 12-18 months.
  • Failure to launch pancreatic bioprint clinical trials by Q4 2027 risks triggering Series B clawback and investor withdrawal.
  • High manufacturing cost of $12,000 per implant versus Novo's $2,000 target blocks commercial viability within 18-24 months.

What makes Aspect Biosystems unique

  • Aspect's full-stack platform integrates AI-powered bioprinting with hypoimmune cell engineering for allogeneic tissue therapeutics.
  • The company develops bioprinted implants using living stem cells and hydrogels to replace or repair organ function.
  • Aspect uniquely targets metabolic and endocrine diseases like diabetes and obesity with functional cures via tissue replacement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

-1%
SFU VentureLabs
Apr 9th, 2026
Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding.

Canadian government supports SFU VentureLabs Alumni, Aspect Biosystems with $79 Million in funding. On April 2nd, the Government of Canada announced an investment of $79 Million for SFU VentureLabs Alumni, Aspect Biosystems. This initiative was conducted through the Strategic Response Fund (SRF), a fund focused on supporting Canadian industries' innovation, adaptation and competition in an evolving global economy. The Province of British Columbia will also be supporting Aspect Biosystems with $23.8 million to expand the company. The national government is strengthening its partnership with Aspect Biosystems with an additional $280 million collaboration that supports the scaling of Aspect's clinical development, enhances their AI-platform and accelerates the commercialization process. This installation will create upwards of 400 jobs for employees and co-op students alike. Aspect Biosystems' CEO, Tamer Mohammed remains enthusiastic about this joint effort. "With this investment and the deepening of our partnership with the Government of Canada, we are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world.", said Mohammed Tamer, CEO of Aspect Biosystems

InBC Investment Corp.
Jan 8th, 2025
Aspect Biosystems Gains InBC Investment Boost

InBC has invested in Vancouver-based Aspect Biosystems, a biotech firm developing bioprinted tissue therapeutics for diseases like diabetes and obesity. The company partners with Novo Nordisk to create treatments for type 1 diabetes. This investment supports Aspect's expansion and aligns with B.C.'s strategy to become a life sciences hub. Aspect previously received funding from Canadian and B.C. governments to enhance its biomanufacturing capabilities.